These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21240643)

  • 21. Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays.
    Kumar S; King LE; Clark TH; Gorovits B
    Bioanalysis; 2015; 7(13):1605-17. PubMed ID: 26226310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toward Accurate and Robust Liquid Chromatography-Mass Spectrometry-Based Quantification of Antibody Biotherapeutics in Tissues.
    An B; Zhang M; Pu J; Qu Y; Shen S; Zhou S; Ferrari L; Vazvaei F; Qu J
    Anal Chem; 2020 Nov; 92(22):15152-15161. PubMed ID: 33155467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
    Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation.
    Kelley M; Ahene AB; Gorovits B; Kamerud J; King LE; McIntosh T; Yang J
    AAPS J; 2013 Jul; 15(3):646-58. PubMed ID: 23543601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 - PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies' inputs on bioanalysis, biomarkers and immunogenicity).
    Neubert H; Olah T; Lee A; Fraser S; Dodge R; Laterza O; Szapacs M; Alley SC; Saad OM; Amur S; Chen L; Cherry E; Cho SJ; Cludts I; Donato LD; Edmison A; Ferrari L; Garofolo F; Haidar S; Hopper S; Hottenstein S; Ishii-Watabe A; Kassim S; Kurki P; Lima Santos GM; Miscoria G; Palandra J; Pedras-Vasconcelos J; Piccoli S; Rogstad S; Saito Y; Savoie N; Sikorski T; Spitz S; Staelens L; Verthelyi D; Vinter S; Wadhwa M; Wang YM; Welink J; Weng N; Whale E; Woolf E; Wu J; Yan H; Yu H; Zhou S
    Bioanalysis; 2018 Dec; 10(23):1897-1917. PubMed ID: 30488729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantification of a bifunctional drug in the presence of an immune response: a ligand-binding assay specific for 'active' drug.
    Staack RF; Jordan G; Viert M; Schäfer M; Papadimitriou A; Heinrich J
    Bioanalysis; 2015 Dec; 7(24):3097-106. PubMed ID: 26484402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.
    Sauerborn M; van Dongen W
    BioDrugs; 2014 Aug; 28(4):383-91. PubMed ID: 24842227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mathematical simulations for bioanalytical assay development: the (un-)necessity and (im-)possibility of free drug quantification.
    Staack RF; Jordan G; Heinrich J
    Bioanalysis; 2012 Feb; 4(4):381-95. PubMed ID: 22394139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Flexible Multiplatform Bioanalytical Strategy for Measurement of Total Circulating Shed Target Receptors: Application to Soluble B Cell Maturation Antigen Levels in the Presence of a Bispecific Antibody Drug.
    Stauffer A; Ray C; Hall M
    Assay Drug Dev Technol; 2021 Jan; 19(1):17-26. PubMed ID: 33232610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling.
    Tiwari A; Abraham AK; Harrold JM; Zutshi A; Singh P
    AAPS J; 2017 Mar; 19(2):510-519. PubMed ID: 28004347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease.
    Chen X; Farrokhi V; Singh P; Ocana MF; Patel J; Lin LL; Neubert H; Brodfuehrer J
    MAbs; 2018 Jan; 10(1):62-70. PubMed ID: 29190188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies.
    Damen CW; Schellens JH; Beijnen JH
    Hum Antibodies; 2009; 18(3):47-73. PubMed ID: 19729801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3 - LBA/cell-based assays: immunogenicity, biomarkers and PK assays).
    Stevenson L; Richards S; Pillutla R; Torri A; Kamerud J; Mehta D; Keller S; Purushothama S; Gorovits B; Litwin V; Stebbins C; Marini J; Beaver C; Sperinde G; Siguenza P; Staack RF; Qiu Y; Amaravadi L; Amur S; Fleener CA; Baltrukonis D; Catlett I; Cherry E; Chung S; Cludts I; Donato LD; Fischer S; Fraser S; Garofolo F; Green C; Gunn G; Haidar S; Haulenbeek J; Henderson N; Hopper S; Ishii-Watabe A; Islam R; Janelsins B; Jawa V; Kakkanaiah V; Kamondi S; Kolaitis G; Kubiak RJ; Kumar S; Kurki P; Liang M; Liu P; Maxfield K; Myler H; Palackal N; Palmer R; Pedras-Vasconcelos J; Piccoli S; Rhyne P; Saito Y; Savoie N; Schick E; Schweighardt B; Shih J; Song A; Sriraman P; Staelens L; Sumner G; Sun Y; Ullmann M; Verthelyi D; Wadhwa M; Wang YM; Xu Y; Yan H; Yang TY; Zeng R
    Bioanalysis; 2018 Dec; 10(24):1973-2001. PubMed ID: 30488726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies.
    Hu L; Hansen RJ
    J Pharm Sci; 2013 Sep; 102(9):2898-908. PubMed ID: 23508847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers.
    Ng CM; Stefanich E; Anand BS; Fielder PJ; Vaickus L
    Pharm Res; 2006 Jan; 23(1):95-103. PubMed ID: 16308668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bioanalysis in the development of antibody-drug conjugates].
    Li XL; Chen XY; Zhong DF
    Yao Xue Xue Bao; 2016 Apr; 51(4):517-28. PubMed ID: 29859519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of bioanalytical methods for the quantitation of PEGylated human insulin.
    de Dios K; Manibusan A; Marsden R; Pinkstaff J
    J Immunol Methods; 2013 Oct; 396(1-2):1-7. PubMed ID: 23933323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues.
    Conner KP; Pastuskovas CV; Soto M; Thomas VA; Wagner M; Rock DA
    MAbs; 2020; 12(1):1746520. PubMed ID: 32310023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platform switching from ELISA to Gyrolab™: a novel generic reagent omits the need to change critical reagents.
    Jordan G; Moheysen-Zadeh M; Heinrich J; Staack RF
    Bioanalysis; 2016 Apr; 8(8):807-14. PubMed ID: 26975340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD.
    Neubert H; Fountain S; King L; Clark T; Weng Y; O'Hara DM; Li W; Leung S; Ray C; Palandra J; Ocaña MF; Chen J; Ji C; Wang M; Long K; Gorovits B; Fluhler E
    Bioanalysis; 2012 Nov; 4(21):2589-604. PubMed ID: 23173794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.